🇺🇸 FDA

Company profile · Sponsor

Acumen

Acumen Pharmaceuticals

ABOS · NYSE biotech NEWTON, MA, USA
Pipeline
4
Drugs
0
Patents
6

Quick answer

Acumen (ABOS) is a biotech company. headquartered in NEWTON, MA, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 6 patents to this profile..

Company facts

Ticker ABOS
Exchange NYSE
Company type biotech
Headquarters NEWTON, MA, USA
SEC CIK 0001576885

Pipeline (4)

Search pipeline →

  1. Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

    Acumen

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

  2. sabirnetug

    Acumen

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  3. ACU193

    Acumen

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  4. sabirnetug (ACU193)

    Acumen

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

Patents (6)

Search patents →

  1. US 9320793

    Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9217024

    ADDL receptor polypeptides, polynucleotides and host cells for recombinant production

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9006283

    Methods of modifying amyloid β oligomers using non-peptidic compounds

    Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8962677

    Methods of restoring cognitive ability using non-peptidic compounds

    Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8507206

    Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7964359

    Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance

    Expires Mon Jun 16 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Acumen?

Acumen (ABOS) is a biotech company. headquartered in NEWTON, MA, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 6 patents to this profile..

What pipeline programs does Acumen sponsor?

We track 4 ClinicalTrials.gov-linked programs for Acumen, including Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Acumen company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.